Available Brands
Did you find this information helpful?
Author Details

Written By
Sakshi Anil More
B. Pharm

Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 08 Oct 2026 | 10:23 AM (IST)

Want to know more?
Read Our Editorial Policy
Quick Summary
RIVASTIGMINE
Last updated on 08 Oct 2026 | 10:23 AM (IST)
RIVASTIGMINE
Molecule Overview
Rivastigmine is a medicine that helps improve thinking ability in people with certain types of dementia by slowing the breakdown of a brain chemical involved in memory and learning. It belongs to a class of medicines called cholinesterase inhibitors, used for mild to moderate Alzheimer's disease and dementia associated with Parkinson's disease. It is a prescription-only medicine, available as capsules, an oral solution, or a transdermal patch.
Medical Classification
Therapeutic Class: Anti-dementia agent.
Pharmacological Class: Cholinesterase inhibitor (acetylcholinesterase and butyrylcholinesterase inhibitor).
Drug Family: Carbamate-derivative cholinesterase inhibitors.
ATC Classification: N06DA03 (Rivastigmine).
Conditions Treated
Approved: Mild to moderate dementia of the Alzheimer's type, and mild to moderate dementia associated with Parkinson's disease (patch formulation also approved for severe Alzheimer's disease).
Commonly used for: Patients diagnosed with Alzheimer's disease or Parkinson's disease dementia who could benefit from support with memory, thinking, and daily functioning.
Off-label use (only under medical guidance): Sometimes considered for other forms of dementia (e.g., Lewy body dementia) under specialist guidance.
Available Strengths & Dosage Forms
Oral capsules: 1.5 mg, 3 mg, 4.5 mg, and 6 mg.
Oral solution: 2 mg/mL.
Transdermal patch: 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours.
How the Molecule Works
In Alzheimer's disease and Parkinson's disease dementia, levels of a brain chemical called acetylcholine, important for memory and learning, become depleted. Rivastigmine blocks the enzymes (acetylcholinesterase and butyrylcholinesterase) that break down acetylcholine, allowing it to build up and have a greater effect on nerve signalling, which can help improve cognitive symptoms, at least temporarily.
Dosage & Administration
Standard dose (oral, Alzheimer's disease): Started at 1.5 mg twice daily, increased gradually (no more than once every two weeks) as tolerated, up to a target range of 6-12 mg per day in divided doses, taken with meals.
Condition-wise dose (patch): Started with the 4.6 mg/24-hour patch once daily; after at least 4 weeks, increased to the 9.5 mg/24-hour patch, and, if needed and tolerated (particularly for severe Alzheimer's disease), further increased to the 13.3 mg/24-hour patch, applied once daily and changed every 24 hours.
Route: Oral (capsules/solution, taken with food in the morning and evening) or transdermal patch (applied to clean, dry, hairless skin on the upper or lower back, upper arm, or chest, with the application site rotated).
Missed dose (patch): Apply a new patch as soon as remembered; if it's almost time for the next patch, skip the missed one and resume the regular schedule — don't apply extra patches to make up for a missed dose.
Overdose: Can cause severe nausea, vomiting, sweating, low blood pressure, slow heart rate, and, in severe cases, muscle weakness or seizures; requires urgent medical attention.
Side Effects
Common: Nausea, vomiting, loss of appetite, weight loss, dizziness, and headache — generally more frequent with oral dosing than with the patch.
Serious: Significant gastrointestinal effects (severe vomiting, dehydration), worsening of parkinsonian symptoms (particularly tremor) in Parkinson's disease dementia patients, and rarely, seizures.
Emergency symptoms: Severe or persistent vomiting, signs of dehydration, significant new tremor or movement difficulty, or a seizure.
Recovery advice: Nausea and appetite loss are more common with oral capsules/solution and often improve with slower dose titration or by switching to the patch, which tends to cause fewer stomach-related side effects.
Warnings & Precautions
Pregnancy: Used only if clearly needed; Alzheimer's disease and Parkinson's disease dementia are not typically conditions affecting women of reproductive age, but caution applies if relevant.
Breastfeeding: Not typically relevant given the patient population; used with medical guidance if applicable.
Liver disease: Used with caution; may require slower dose titration.
Kidney disease: Used with caution; may require slower dose titration, given reduced clearance.
Elderly: This is the primary population for whom rivastigmine is used, given the age profile of Alzheimer's and Parkinson's disease dementia.
Children: Not approved for use in children; dose and use must be determined by a doctor if ever considered off-label.
Drug Interactions
Other cholinergic medicines (e.g., bethanechol) or cholinesterase inhibitors: combined use can increase cholinergic side effects and is generally avoided.
Anticholinergic medicines (e.g., certain antihistamines, atropine, benztropine, trihexyphenidyl): oppose rivastigmine's effect and should generally be avoided during treatment.
Muscle relaxants used during anesthesia (succinylcholine-type): rivastigmine may prolong the effect of these medicines during surgery; anesthesia providers should be informed.
Unlike some other cholinesterase inhibitors, rivastigmine does not significantly raise blood levels of other medications through major drug-metabolising enzyme pathways.
Monitoring Requirements
Weight monitoring, given the risk of appetite loss and weight loss.
Assessment for gastrointestinal side effects, particularly during dose increases.
Monitoring for worsening tremor or movement symptoms in Parkinson's disease dementia patients.
Periodic cognitive/functional assessment to gauge ongoing treatment benefit.
Alternative Molecules
Donepezil, Galantamine (other cholinesterase inhibitors); Memantine (a different mechanism, NMDA receptor antagonist, sometimes used in combination).
Combination Therapies
Sometimes used alongside memantine, particularly as Alzheimer's disease progresses to moderate-to-severe stages; not combined with other cholinesterase inhibitors.
Alzheimer's Disease Medicines
Parkinson's Disease Dementia Treatments
Cholinesterase Inhibitors
FAQs
Q1.
It's used to help manage symptoms of mild to moderate Alzheimer's disease and dementia associated with Parkinson's disease, and severe Alzheimer's disease with the patch formulation.
Q2.
No, it doesn't cure or stop the underlying disease, but it can help improve or stabilise cognitive symptoms for a period of time.
Q3.
The patch tends to cause fewer stomach-related side effects like nausea and vomiting compared with oral capsules or solution, while still delivering effective drug levels.
Q4.
To clean, dry, hairless skin on the back, upper arm, or chest, changed once every 24 hours, with the application site rotated to avoid skin irritation.
Q5.
Yes, it can occasionally worsen tremor or other parkinsonian symptoms, so this is monitored, particularly in patients being treated for Parkinson's disease dementia.
References
Disclaimer
The information on this page is for educational purposes only and is not a substitute for medical advice. Please consult your doctor to know if this treatment is appropriate for your condition.






